We started Minomic with a handful of people in 2007 convinced that biomarkers would be the next big thing in the diagnosis and treatment of human disease.

We are now on the cusp of bringing to market the MiCheck test, a new, non-invasive test for prostate cancer.

Using only a simple blood sample, the MiCheck test detects a protein that is present on cancer cells. It's shaping up to be more effective than existing tests and is almost ready for prime time.

Imagine collecting a sample and being able to tell whether the patient has prostate cancer.

You won't have to imagine for long.

  • 2007

    Minomic International Founded

  • 2009

    Showed antibody binding to prostate cancer cells

  • 2011

    Received VC funding for commercialisation

  • 2012

    First patient trial completed

  • 2014

    Clinical validation studies

  • 2015

    Regulatory framework and approvals

  • 2016

    Early commercialisation

Minomic Logo and Press Kit

You're free to use the Minomic trademark in published articles, press releases, in your blog and similar use cases.

The Minomic Press Kit includes:

  • Background information
  • Hi-res logos

Want to know when it's ready or learn more?

We'll be providing more and detailed information as we reach our milestones